Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.

This is highly significant as it provides the potential to enable dosing with EphA4 Fc at weekly intervals as opposed to the glycosylated protein which would need to be delivered daily or by continuous infusion to be effective as a decoy receptor drug.

also in 132,142 other papers